ACM
Aquilo Capital Management Portfolio holdings
AUM
$37.1M
This Quarter Return
+20.9%
1 Year Return
-36.49%
3 Year Return
+1.32%
5 Year Return
+39.69%
10 Year Return
–
AUM
$147M
AUM Growth
+$147M
(+67%)
Cap. Flow
+$40.4M
Cap. Flow
% of AUM
27.41%
Top 10 Holdings %
Top 10 Hldgs %
99.85%
Holding
13
New
3
Increased
5
Reduced
–
Closed
1
Top Buys
| 1 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
$13.5M |
| 2 |
Regenxbio
RGNX
|
$11M |
| 3 |
ProQR Therapeutics
PRQR
|
$10.8M |
| 4 |
PVLA
Palvella Therapeutics, Inc. Common Stock
PVLA
|
$7.19M |
| 5 |
Galapagos
GLPG
|
$3.13M |
Top Sells
| 1 |
BCYC
Bicycle Therapeutics
BCYC
|
$8.74M |
Sector Composition
| 1 | Healthcare | 90.81% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
uniQure
QURE
$896M
| $28.4M | 10.68% |
396,899
+5,700
| +1% | +$408K |
|
|
2
ProQR Therapeutics
PRQR
$237M
| $19.1M | 7.16% |
1,922,570
+1,090,909
| +131% | +$10.8M |
|
|
PVLA
3
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $17.8M | 6.67% |
4,966,820
+2,008,577
| +68% | +$7.19M |
|
4
Xenon Pharmaceuticals
XENE
$2.98B
| $15.3M | 5.75% |
1,166,736
+215,209
| +23% | +$2.82M |
|
|
5
Galapagos
GLPG
$2.07B
| $14.9M | 5.59% |
71,967
+15,127
| +27% | +$3.13M |
|
6
Merus
MRUS
$4.98B
| $14.6M | 5.49% |
1,038,746
| – | – |
|
|
DRNA
7
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $13.5M | 5.08% |
+614,436
| New | +$13.5M |
|
8
Spero Therapeutics
SPRO
$116M
| $11.1M | 4.17% |
1,154,356
| – | – |
|
|
9
Regenxbio
RGNX
$451M
| $11M | 4.14% |
+268,778
| New | +$11M |
|
10
Fate Therapeutics
FATE
$120M
| $1.41M | 0.53% |
72,273
| – | – |
|
|
MOR
11
DELISTED
MorphoSys AG American Depositary Shares
MOR
| $217K | 0.08% |
+6,080
| New | +$217K |
|
|
BCYC
12
Bicycle Therapeutics
BCYC
$511M
| – | – |
-767,026
| Closed | -$8.74M |
|
13
SPDR S&P Biotech ETF
XBI
$5.07B
| – | – |
0
| – | – |
|